168 related articles for article (PubMed ID: 32505524)
21. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
Edmondson C; Course CW; Doull I
Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533
[TBL] [Abstract][Full Text] [Related]
22. Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis.
Stylemans D; Darquenne C; Schuermans D; Verbanck S; Vanderhelst E
J Cyst Fibros; 2022 Jan; 21(1):160-163. PubMed ID: 33832855
[TBL] [Abstract][Full Text] [Related]
23. Clinical papers of the year 2018 - Cystic fibrosis.
Balfour-Lynn IM
Paediatr Respir Rev; 2020 Feb; 33():58-61. PubMed ID: 31053358
[TBL] [Abstract][Full Text] [Related]
24. Tribulations and (clinical) trials in cystic fibrosis.
Cagnina RE; Sawicki GS
J Cyst Fibros; 2021 Mar; 20(2):188-190. PubMed ID: 33408059
[No Abstract] [Full Text] [Related]
25. Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis.
DiMango E; Overdevest J; Keating C; Francis SF; Dansky D; Gudis D
J Cyst Fibros; 2021 May; 20(3):460-463. PubMed ID: 32694034
[TBL] [Abstract][Full Text] [Related]
26. Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.
Lyman BC; Seay J; Contreary C; Savant AP; Dell ML; Hescock GC
Pediatr Pulmonol; 2022 Dec; 57(12):3174-3176. PubMed ID: 35962539
[No Abstract] [Full Text] [Related]
27. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
Elborn JS; Davies J
Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
[No Abstract] [Full Text] [Related]
28. Effects of elexacaftor/tezacaftor/ivacaftor on liver fibrosis markers in adults with cystic fibrosis.
Tewkesbury DH; Scott J; Barry PJ; Bright-Thomas RJ; Hanley KP; Athwal V; Jones AM
J Cyst Fibros; 2024 Mar; 23(2):349-353. PubMed ID: 37735009
[TBL] [Abstract][Full Text] [Related]
29. Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test.
Mir-Ihara P; De Las Vecillas L; Heredia R; Fiandor A; González-Muñoz M; Zamarrón E; Prados C; Cabañas R
J Investig Allergol Clin Immunol; 2024 Jun; 34(3):211-213. PubMed ID: 37966860
[No Abstract] [Full Text] [Related]
30. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.
Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662
[No Abstract] [Full Text] [Related]
31. The effectiveness and value of novel treatments for cystic fibrosis.
Tice JA; Kuntz KM; Wherry K; Seidner M; Rind DM; Pearson SD
J Manag Care Spec Pharm; 2021 Feb; 27(2):276-280. PubMed ID: 33506736
[No Abstract] [Full Text] [Related]
32. Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series.
O'Connor KE; Goodwin DL; NeSmith A; Garcia B; Mingora C; Ladores SL; Rowe SM; Krick S; Solomon GM
J Cyst Fibros; 2021 May; 20(3):399-401. PubMed ID: 33353860
[TBL] [Abstract][Full Text] [Related]
33. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
34. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Mall MA; Mayer-Hamblett N; Rowe SM
Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
[TBL] [Abstract][Full Text] [Related]
35. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
Mitchell RM; Jones AM; Barry PJ
Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
[TBL] [Abstract][Full Text] [Related]
36. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
Egan ME
Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
[TBL] [Abstract][Full Text] [Related]
37. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation.
Taylor-Cousar JL; Jain R
J Cyst Fibros; 2021 May; 20(3):402-406. PubMed ID: 33762125
[TBL] [Abstract][Full Text] [Related]
38. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Heltshe SL; Cogen J; Ramos KJ; Goss CH
Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
[No Abstract] [Full Text] [Related]
39. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR; Durieu I; Chiron R; Ramel S; Danner-Boucher I; Prevotat A; Grenet D; Marguet C; Reynaud-Gaubert M; Macey J; Mely L; Fanton A; Quetant S; Lemonnier L; Paillasseur JL; Da Silva J; Martin C;
Am J Respir Crit Care Med; 2021 Jul; 204(1):64-73. PubMed ID: 33600738
[No Abstract] [Full Text] [Related]
40. At-home compounding preparation of slow desensitization of elexacaftor/tezacaftor/ivacaftor for delayed hypersensitivity rash.
Muirhead C; Verzasconi D; Joshi S
Pediatr Pulmonol; 2022 Jul; 57(7):1779-1781. PubMed ID: 35451238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
